Prevention and Treatment of Lower Limb Deep Vein Thrombosis after Radiofrequency Catheter Ablation: Results of a Prospective active controlled Study
Clinical trial published in Scientific reports (2016)
Abstract
We conducted a prospective, single-center, active controlled study from July 2013 to January 2015, in Chinese patients with rapid ventricular arrhythmia who had received radiofrequency catheter ablation (RFCA) treatment to determine formation of lower extremity deep vein thrombosis (LDVT) post RFCA procedure, and evaluated the effect of rivaroxaban on LDVT. Patients with asymptomatic pulmonary thromboembolism who had not received any other anticoagulant and had received no more than 36 hours of treatment with unfractionated heparin were included. Post RFCA procedure, patients received either rivaroxaban (10 mg/d for 14 days beginning 2-3 hours post-operation; n = 86) or aspirin (100 mg/d for 3 months beginning 2-3 hours post-operation; n = 90). The primary outcome was a composite of LDVT occurrence, change in diameter of femoral veins, and safety outcomes that were analyzed based on major or minor bleeding events. In addition, blood flow velocity was determined. No complete occlusive thrombus or bleeding events were reported with either of the group. The lower incidence rate of non-occluded thrombus in rivaroxaban (5.8%) compared to the aspirin group (16.7%) indicates rivaroxaban may be administered post-RFCA to prevent and treat femoral venous thrombosis in a secure and effective way with a faster inset of action than standard aspirin therapy.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
We conducted a prospective, single-center, active controlled study from July 2013 to January 2015, in Chinese patients with rapid ventricular arrhythmia who had received radiofrequency catheter ablation (RFCA) treatment to determine formation of lower extremity deep vein thrombosis (LDVT) post RFCA procedure, and evaluated the effect of rivaroxaban on LDVT.
Por qué esto importa para la hirudoterapia
Este estudio prospectivo, controlado con activo, evaluó la eficacia y la seguridad de rivaroxabán frente a aspirina en la prevención de la trombosis venosa profunda (TVP) de las extremidades inferiores en 176 pacientes chinos tras ablación por catéter con radiofrecuencia. El estudio encontró que rivaroxabán produjo una menor incidencia de trombo no oclusivo en comparación con aspirina, sin trombos oclusivos completos ni eventos hemorrágicos. No existe relevancia directa para la American Society of Hirudotherapy, la terapia con sanguijuelas ni el secretoma de la sanguijuela, ya que el resumen no menciona sanguijuelas, hirudina ni ningún compuesto derivado de sanguijuelas. La investigación se centra únicamente en comparar anticoagulantes y antiagregantes plaquetarios farmacéuticos estándar para el manejo de la trombosis venosa posprocedimiento, sin aportar datos aplicables a la investigación en hirudoterapia.
Citación
Prevention and Treatment of Lower Limb Deep Vein Thrombosis after Radiofrequency Catheter Ablation: Results of a Prospective active controlled Study
Li L et al. · Scientific reports, 2016
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026